ALNY
The growth story is still very much alive
Alnylam Pharmaceuticals said it reported second-quarter 2026 financial results and highlighted recent business progress, which is corporate-speak for: the company wants you to notice that the story is still getting better. After crossing the $1 billion quarterly product revenue mark for the first time in its history in Q1, Alnylam says it kept building on that momentum in the first half of the year.
Why investors care
For a company like Alnylam, the key question is whether blockbuster-level revenue growth can keep outrunning the costs of being a biotech that’s still investing hard in future products. That means investors will be parsing the usual suspects: product sales trends, operating expenses, and whether management sounds confident enough to keep the hype train rolling.
The bigger picture
Alnylam isn’t just selling a quarter. It’s selling a thesis: that RNAi can keep moving from sci-fi-adjacent promise into a real, durable drug franchise. If the company can keep stacking revenue milestones, the market may be willing to give it more credit for being a growth biotech with actual scale instead of just a research story.
Big picture: the market loves a company that can turn “next big thing” into “actually big thing.” Alnylam is trying to do exactly that.